New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 20, 2013
16:23 EDTACHNAchillion reports Q4 EPS (14c), consensus (20c)
Reports Q4 revenue $118,000, no consensus available.
News For ACHN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 26, 2014
13:35 EDTACHNAchillion volatility elevated
Subscribe for More Information
13:25 EDTACHNAchillion to benefit from Bristol-Myers CRL, says FBR Capital
FBR Capital expects Achillion (ACHN) to benefit from the complete response letter that the FDA sent to Bristol-Myers (BMY) on its daclatasvir HCV drug. The firm thunks the letter increases the value of GT-3 HCV patients for Achillion. FBR says that GT-3 patients constitute 5% of HCV patients in the U.S. and significantly higher in Europe. It keeps an Outperform rating on Achillion.
13:11 EDTACHNAchillion mentioned positively at FBR Capital
06:07 EDTACHNStocks with implied volatility above IV index mean; DG ACHN
Subscribe for More Information
November 19, 2014
05:44 EDTACHNStocks with implied volatility movement; MCD KO
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use